Abstract
The use of CO2 as a carbon source in biorefinery is of great interest, but the low solubility of CO2 in water and the lack of efficient CO2 assimilation pathways are challenges to overcome. Formic acid (FA), which can be easily produced from CO2 and more conveniently stored and transported than CO2, is an attractive CO2‐equivalent carbon source as it can be assimilated more efficiently than CO2 by microorganisms and also provides reducing power. Although there are native formatotrophs, they grow slowly and are difficult to metabolically engineer due to the lack of genetic manipulation tools. Thus, much effort is exerted to develop efficient FA assimilation pathways and synthetic microorganisms capable of growing solely on FA (and CO2). Several innovative strategies are suggested to develop synthetic formatotrophs through rational metabolic engineering involving new enzymes and reconstructed FA assimilation pathways, and/or adaptive laboratory evolution (ALE). In this paper, recent advances in development of synthetic formatotrophs are reviewed, focusing on biological FA and CO2 utilization pathways, enzymes involved and newly developed, and metabolic engineering and ALE strategies employed. Also, future challenges in cultivating formatotrophs to higher cell densities and producing chemicals from FA and CO2 are discussed.
Keywords: formatotroph, formic acid assimilation, one‐carbon biorefinery, systems metabolic engineering
This paper reviews the recent advances in developing synthetic FA and CO2 assimilation pathways and formatotrophs. Moreover, chemicals that can be produced from FA and CO2 together with the strategies for metabolic engineering of the formatotrophic Escherichia coli to produce these chemicals are discussed. This review provides things to consider for building a sustainable one‐carbon biorefinery.
1. Introduction
Bio‐based production of chemicals, fuels, and materials has been mostly relying on carbohydrates prepared from biomass as raw materials. The use of CO2 as a carbon source for microbial production of chemicals[ 1 , 2 , 3 , 4 ] has attracted much attention as CO2 is abundant (e.g., industrial off‐gas) and inexpensive.[ 5 , 6 ] Moreover, the utilization of CO2 as a carbon source can contribute to reducing atmospheric CO2, which is beneficial to cope with climate crisis.[ 7 , 8 ] Hence, numerous studies have been carried out to increase CO2 assimilation using natural CO2 assimilation pathways,[ 9 , 10 , 11 , 12 ] including the Calvin–Benson–Bassham (CBB) cycle, and to use these pathways for the conversion of CO2 to chemicals.[ 13 , 14 , 15 , 16 ] However, the carboxylases, such as ribulose‐1,5‐bisphosphate carboxylase/oxygenase (Rubisco), involved in the natural CO2 assimilation pathways exhibit low catalytic rates and have a tendency to confuse CO2 with O2.[ 17 ] In addition, engineering of Rubisco for more efficient carboxylation has not been successful due to the existence of trade‐off between the maximum turnover rate and CO2/O2 affinity.[ 17 , 18 ] The reason for such behavior is unclear as the reaction mechanism of this enzyme has not been fully studied.
To overcome the limitation of direct CO2 assimilation in the natural CO2 assimilation pathways, formic acid (FA) and methanol, both of which can be produced by electrochemical reduction of CO2,[ 19 , 20 ] have been employed as alternative carbon sources equivalent to CO2 for the following reasons. FA and methanol are easier to store and transport than CO2;[ 21 , 22 , 23 , 24 ] FA and methanol can be assimilated by microorganisms more efficiently than CO2 as both chemicals are more soluble in water and can be metabolized better compared with CO2.[ 22 ] Between FA and methanol, FA is a better carbon source than methanol as pure FA can be easily produced from CO2 using electrochemical[ 19 ] or catalytic processes,[ 25 ] while the production of methanol from CO2 is less efficient as CO and FA are also formed as byproducts.[ 26 ] Thus, this review focuses on the studies associated with the utilization of FA as a carbon source together with CO2.
Native formatotrophs, such as Methylobacterium extorquens, can grow using FA as a sole carbon source.[ 27 ] However, native formatotrophs grow slowly and are sensitive to culture conditions. Also, they are rather difficult to metabolically engineer due to the lack of efficient genetic manipulation tools compared with well‐known host strains such as Escherichia coli. In addition, the native FA assimilation pathways, including serine and reductive acetyl‐CoA pathways, present in the native formatotrophs are kinetically and energetically inefficient.[ 23 ] Thus, studies on FA assimilation have mainly been carried out using metabolically engineered microorganisms (e.g., E. coli) harboring synthetic FA assimilation pathways.[ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ] Taking advantage of well‐established methods and strategies for metabolic engineering, E. coli has often been employed as a base strain to establish synthetic FA assimilation pathways and develop synthetic formatotrophs.
In recent studies, various synthetic formatotrophic E. coli strains have been developed to establish one‐carbon biorefinery.[ 33 , 34 , 35 ] However, the highest cell density achieved by the formatotrophic E. coli strain was 3.47 g dry cell weight (gDCW) L−1, which is significantly lower than that (128 gDCW L−1) of an E. coli strain cultivated using a conventional carbon source such as glucose.[ 36 ] The main reasons for the poor cell growth of formatotrophic E. coli strain are: low FA assimilation efficiency,[ 31 ] insufficient generation of reducing power from FA,[ 34 ] and low FA tolerance of E. coli.[ 35 , 37 , 38 ] Thus, these problems need to be solved to establish an economically competitive one‐carbon biorefinery.
In this paper, we review recent advances in constructing FA assimilation pathways and developing formatotrophic E. coli strains. Also, metabolic engineering strategies for further improving the growth of the formatotrophic E. coli strains are discussed. In addition, we present strategies for the metabolic engineering of formatotrophic E. coli to produce several example chemicals, including lactic acid (LA), L‐alanine, L‐serine, and succinic acid (SA), from FA and CO2 as sole carbon sources. Finally, fermentation processes that can further enhance formatotrophic growth of E. coli and production of chemicals from FA and CO2 are suggested.
2. Overview on the Development of Formatotrophic E. coli Strains
Studies on the development of formatotrophic E. coli strains up to date can be summarized as follows. To enable E. coli to utilize FA only or FA and CO2, various synthetic FA assimilation pathways (Table 1 ) were constructed by the development of novel enzymes,[ 39 ] enzyme engineering,[ 40 ] and reconstruction of FA assimilation pathways (Figure 1 ).[ 28 , 29 , 30 , 31 ] The synthetic FA assimilation pathways lead to the biosynthesis of one of the three core metabolites, acetyl‐CoA, dihydroxyacetone phosphate (DHAP), and pyruvate, from FA only or FA and CO2 (Figure 2 ). In these initial studies, however, other carbon sources such as glucose were still needed to provide reducing power for cell growth. Thus, strategies for generating reducing power from FA by introducing a heterologous formate dehydrogenase (Fdh) was employed (Figure 1).[ 31 ] Furthermore, adaptive laboratory evolution (ALE) and/or rational metabolic engineering were performed using the FA and CO2 assimilating E. coli strains to achieve formatotrophic growth (Figure 1 and Table 2 ).[ 33 , 34 , 35 ] In a previous study, the Rubisco‐dependent heterotrophic E. coli strain was evolved to achieve formatotrophic growth up to an optical density (OD 600) of 0.28 by cultivating the cells in a xylose‐limited chemostat with excess sodium FA and continuous sparging of CO2‐enriched air.[ 33 ] In another study, a short‐term ALE by serial cultivations of a formatotorophic E. coli strain, which was developed by introducing a synthetic FA and CO2 assimilation pathway in the serine‐auxotrophic E. coli strain, improved formatotrophic growth enabling the formatotorophic E. coli strain to grow up to an OD 600 of 1.0.[ 34 ] In a most recent study, a rationally engineered E. coli strain capable of growing to a relatively high cell density (OD 600 of ≈11) using FA and CO2 as sole carbon sources[ 35 ] was developed. We describe detailed strategies employed for developing these formatotrophic E. coli strains below.
Table 1.
Pathway | Substrate(s) | Product | Required amount of ATP and reducing power a) | Description | Reference(s) |
---|---|---|---|---|---|
Formolase pathway | FA | Dihydroxyacetone phosphate | 4 ATP and 3 NADH |
|
[ 39 ] |
Synthetic acetyl‐CoA pathway | FA | Acetyl‐CoA | 2 ATP and 2 NADH |
|
[ 40 ] |
Reconstructed THF cycle and reverse glycine cleavage pathway | FA and CO2 | Pyruvate | 2 ATP, 1 NADH, and 2 NADPH |
|
[ 29 , 30 , 31 ] |
Modified serine cycle | FA and CO2 | Acetyl‐CoA | 3 ATP, 1 NADH, and 2 NADPH |
|
[ 47 ] |
Synthetic homoserine cycle | FA | Acetyl‐CoA | 1 ATP and 1 NADH |
|
[ 48 ] |
Total amount of ATP and reducing powers (NADH and NADPH) required to synthesize one molecule of product from FA or FA and CO2.
Table 2.
Strain | Initial OD 600 | Final OD 600 | Cultivation time [h] | Doubling time [h] | FA assimilation pathway b) | Description | Reference |
---|---|---|---|---|---|---|---|
E. coli | 0.91 | 11.1 | 577 | 157.6 | rTHF‐rgcv and Fdh |
|
[ 35 ] |
E. coli | 0.31 | 0.5 | 77 | N/A c) | rTHF‐rgcv and Fdh |
|
[ 31 ] |
E. coli | 0.01 a) | 0.28 a) | 120 a) | 18 ± 4 | CBB and Fdh |
|
[ 33 ] |
E. coli | 0.01 a) | 1.0 a) | 60 | 7.7 | rTHF‐rgcv and Fdh |
|
[ 34 ] |
Abbreviations are rTHF, reconstructed tetrahydrofolate cycle; rgcv, reverse glycine cleavage pathway; Fdh, formate dehydrogenase; CBB, Calvin–Benson–Bassham cycle; ALE, adaptive laboratory evolution.
Values estimated using the data provided in corresponding study.
FA assimilation pathway employed by the formatotrophic E. coli strain.
Not available.
3. Formic Acid Assimilation to Intracellular Metabolites through Synthetic Formic Acid Assimilation Pathways
3.1. Development of Synthetic Formic Acid Assimilation Pathways
To produce chemicals from FA in E. coli, FA needs to be assimilated to intracellular metabolites. For this purpose, synthetic FA assimilation pathways were constructed using de novo enzymes catalyzing the FA assimilation reactions and/or by reconstructing the FA assimilation pathways.
In a previous study, the synthetic formolase (Fls) pathway[ 39 ] was employed in E. coli to produce one DHAP molecule from three FA molecules using four ATP and three NADH molecules (Figure 2a and Table 1). In this pathway, FA is converted to DHAP through four steps of enzymatic reactions. First, FA is converted to formyl‐CoA by native acetyl‐CoA synthase (Acs) and further converted to formaldehyde (FALD) by Listeria monocytogenes acetaldehyde dehydrogenase (Acdh). Next, one molecule of dihydroxyacetone (DHA) is synthesized through carbon‐carbon bonding of three molecules of FALD by Fls, which is an enzyme developed in this study. The Fls was designed by computational method using Pseudomonas fluorescens benzaldehyde lyase as a template. The binding pocket of benzaldehyde lyase for benzaldehyde was engineered to possess higher affinity toward FALD based on RosettaDesign[ 43 ] and Foldit[ 44 ] and the catalytic efficiency of Fls was improved by further performing error‐prone PCR. Finally, DHA kinase (Dhak) was utilized to convert DHA to DHAP, which is further utilized to synthesize intracellular metabolites through glycolysis and gluconeogenesis. The Fls pathway can be easily introduced into other microorganisms, since only four different enzymes are required to operate this pathway. However, low enzyme activity of the Fls was a major drawback for FA assimilation through the Fls pathway. Due to low enzyme activity of the Fls (catalytic efficiency; kcat/km = 4.7 s−1 M−1), FA assimilation through the Fls pathway was only confirmed in vitro. Thus, employing the Fls pathway in E. coli for FA assimilation can be challenging.
In another study, the synthetic acetyl‐CoA (SACA) pathway[ 40 ] was introduced in E. coli to produce one acetyl‐CoA molecule from two FA molecules using two ATP and two NADH molecules (Figure 2b and Table 1). In this pathway, FALD is first synthesized from FA by Acs and Acdh, similar to the Fls pathway.[ 39 ] Next, one molecule of glycolaldehyde is synthesized from two FALD molecules by glycolaldehyde synthase (Gals), which is an enzyme developed in this study. The Gals was developed by directed evolution of Pseudomonas putida benzoylformate decarboxylase (Bfd). Since Fls was demonstrated to synthesize DHA from FALD,[ 39 ] the amino acid sequences of Bfd and Fls were aligned to predict the FALD binding site in the Bfd and the residues of the Bfd, which correspond to the key residues in the FALD binding site of the Fls, were mutated to develop Gals. Finally, Saccharomonospora marina acetyl‐phosphate synthase was employed to convert glycolaldehyde to acetyl‐phosphate, which is further converted to acetyl‐CoA by native phosphate acetyltransferase (Pta). The synthetic SACA pathway, which includes five reaction steps, enables acetyl‐CoA production from FALD. However, employing the SACA pathway in E. coli for FA assimilation can be challenging due to the low enzyme activity of Gals (kcat/km = 9.29 s−1 M−1). It should be noted that the catalytic efficiency of Moorella thermoacetica formate‐tetrahydrofolate (THF) ligase (Ftl), which is a natural FA assimilating enzyme, is 2450.98 s−1 M−1.[ 45 ]
The utilization of de novo enzymes allows construction of short and simple synthetic FA assimilation pathways and production of target chemicals directly from FA. However, low enzyme activities of the novel enzymes are a major drawback for the synthetic FA assimilation pathways employing such enzymes. On the other hand, the native FA assimilation pathways consist of more enzymatic reactions than the synthetic FA assimilation pathways employing de novo enzymes. In addition, it is difficult to employ the native FA assimilation pathways for chemical production as the reactions involved in the native FA assimilation pathways are kinetically (e.g., Rubisco)[ 17 ] and energetically inefficient (e.g., CBB cylce requires 7 ATP and 4 NAD(P)H to synthesize 1 acetyl‐CoA molecule; refer to Table 1 for comparison).[ 23 ] Also, the pathway produces toxic intermidiates, such as hydroxypyruvate.[ 46 ] Thus, a different approach that involves the reconstruction of FA assimilation pathways was undertaken to develop synthetic FA assimilation pathways.
In previous studies, the synthetic FA assimilation pathways comprising the reconstructed THF cycle and reverse glycine cleavage pathway (Figure 2c and Table 1), named as rTHF‐rgcv pathway hereafter, were constructed in E. coli to enable FA assimilation.[ 29 , 30 , 31 ] In these pathways, one molecule of FA is incorporated into THF by the heterologous expression of the ftl gene (encoding Ftl), producing formyl‐THF (10‐CHO—THF). Next, the heterologous 5,10‐methenyl‐THF (5,10‐CH=THF) cyclohydrolase (Fch) converts 10‐CHO—THF to 5,10‐CH=THF, which is further converted to 5,10‐methylene‐THF (5,10‐CH2—THF) by the heterologous 5,10‐CH2—THF dehydrogenase (Mtd). The heterologous genes encoding Ftl, Fch, and Mtd were all obtained from Clostridium ljungdahlii [ 29 ] or M. extorquens.[ 30 , 31 ] Then, 5,10‐CH2—THF and glycine, which is synthesized using 5,10‐CH2—THF, CO2, and NH3 through the gcv pathway, were converted to THF and L‐serine by the native serine hydroxymethyltransferase (GlyA). Finally, pyruvate is produced from L‐serine by the native serine deaminase (Sda). The synthetic FA assimilation pathway, comprising rTHF‐rgcv pathway, synthesizes one pyruvate molecule from two FA molecules and one CO2 molecule, consuming two ATP, two NADPH, and one NADH molecules (Table 1). This synthetic FA assimilation pathway is promising because the enzymes employed for FA assimilation were selected from native formatotrophs, which possess much higher enzyme activities[ 45 ] than those of de novo enzymes.[ 39 , 40 ] In addition, the theoretical maximum biomass yield by this synthetic FA assimilation pathway (5.7 gDCW mol of FA−1) was calculated to be the highest compared to those of other native and synthetic FA assimilation pathways (CBB cycle, 4.8 gDCW mol of FA−1; Fls pathway, 4.9 gDCW mol of FA−1; serine cycle, 5 gDCW mol of FA−1) based on flux balance analysis using E. coli metabolic model.[ 41 ] Most importantly, pyruvate can be easily converted to diverse chemicals through the native metabolic pathways in E. coli.
In another study, a modified serine cycle, which produces one pyruvate molecule from two FA and one CO2 molecules, was constructed in E. coli (Figure 2d and Table 1).[ 47 ] In this pathway, FA and glycine are used to produce L‐serine through the THF cycle and the synthesized L‐serine is further utilized to run the serine cycle. In the serine cycle, L‐serine is converted to phosphoenolpyruvate (PEP) by sequential reactions of Sda and PEP synthase (encoded by the ppsA gene). Next, CO2 is assimilated by the native PEP carboxylase to convert PEP to oxaloacetate, which is further converted to malate by the native malate dehydrogenase. The synthesized malate is converted to malyl‐CoA by the native malate thiokinase and further broken down into glyoxylate and acetyl‐CoA by malyl‐CoA lyase. Finally, acetyl‐CoA is converted to pyruvate by the reverse reaction of native pyruvate formate lyase (Pfl) and glyoxylate is converted to glycine, which is reutilized to operate the THF cycle, by the native alanine‐glyoxylate transaminase.[ 42 ] Although the modified serine cycle produces pyruvate from FA and CO2, similar to the synthetic FA assimilation pathway comprising the rTHF‐rgcv pathway, it displays two weaknesses. First, the modified serine cycle requires three ATP, one NADPH, and two NADH molecules (Table 1). Thus, one more ATP is consumed to operate the modified serine cycle for the production of one pyruvate molecule than operating the synthetic FA assimilation pathway comprising the rTHF‐rgcv pathway (Table 1). Second, the modified serine cycle is complex and employs more enzymatic reactions than the synthetic FA assimilation pathway comprising the rTHF‐rgcv pathway, which is an undesirable feature for further metabolic engineering.
In a most recent study, the synthetic homoserine cycle was constructed in E. coli by the reconstruction of serine cycle (Figure 2e and Table 1).[ 48 ] In this pathway, FALD, which is produced from FA by Acs and Acdh, is incorporated into glycine to produce L‐serine by the native serine aldolase. L‐serine is deaminated by the native Sda to produce pyruvate and an additional FALD molecule is combined with pyruvate to synthesize 4‐hydroxy‐2‐oxobutanoate (HOB) using native 4‐hydroxy‐2‐oxobutanoate aldolase. Next, the native HOB aminotransferase converts HOB to homoserine, which is further converted to glycine and acetaldehyde by sequential reactions of native homoserine kinase, threonine synthase, and threonine aldolase. Finally, glycine is reused for the production of L‐serine while acetaldehyde is converted to acetyl‐CoA by the native Acdh. The synthetic homoserine cycle synthesizes one acetyl‐CoA molecule from two FA molecules consuming one ATP and one NADH molecules, while the modified serine cycle consumes three ATP, one NADPH, and two NADH molecules to synthesize one acetyl‐CoA molecule (Figure 2d and Table 1). Thus, the synthetic homoserine cycle is more energy efficient than the modified serine cycle. However, FALD, which is a cytotoxic compound,[ 49 ] is produced as an intermediate in the synthetic homoserine cycle during FA assimilation. Moreover, biosynthesis of acetyl‐CoA from FA is less desirable than production of pyruvate or DHAP.
Among the synthetic FA assimilation pathways developed to date, the rTHF‐rgcv pathway is the best choice for FA and CO2 assimilation. The rTHF‐rgcv pathway is simple and requires fewer enzymatic reactions than the modified serine cycle. In addition, while the rTHF‐rgcv pathway directly assimilates FA and CO2, the Fls pathway, SACA pathway, and synthetic homoserine cycle require an additional step for converting FA to FALD, which is highly toxic to living cells.[ 49 ] Therefore, FA assimilation in E. coli using the rTHF‐rgcv pathway will be the focus for the remainder of this review.
3.2. Further Engineering of the Reconstructed rTHF‐rgcv Pathway
To improve FA assimilation to intracellular metabolites using the rTHF‐rgcv pathway, the native metabolic pathways in E. coli had to be engineered because the native metabolic pathways could influence the FA assimilation efficiency of the rTHF‐rgcv pathway. In a study by Tashiro et al.,[ 29 ] the FA assimilation efficiency of the E. coli strain equipped with the rTHF‐rgcv pathway was enhanced by the introduction of the ftl and fch genes from C. ljungdahlii and the replacement of native folD gene encoding the bifunctional 5,10‐CH2—THF dehydrogenase/5,10‐CH2—THF cyclohydrolase, which is allosterically inhibited by 10‐CHO—THF,[ 50 ] with the C. ljungdahlii folD gene (Figure 3 ). In addition, the native gcvTHP operon encoding gcv complex was overexpressed to improve glycine production from CO2 and 5,10‐CH2—THF. Moreover, the serA gene encoding phosphoglycerate dehydrogenase was deleted to allow L‐serine production only from FA and CO2 by preventing L‐serine production from glucose. Finally, the native sda gene was overexpressed to increase conversion of L‐serine to pyruvate. Although the metabolic engineering strategies employed in the study by Tashiro et al. had increased FA assimilation in E. coli, the level of FA assimilation to L‐serine and pyruvate was insufficient to facilitate formatotrophic growth; less than 10% and 1.5% of proteinogenic L‐serine and total pyruvate, respectively, were synthesized from FA and CO2.
FA assimilation of the engineered E. coli strain possessing the rTHF‐rgcv pathway was further improved by Yishai et al.[ 30 ] and by Bang and Lee[ 31 ] (Figure 3). Similar metabolic engineering strategies were employed in both studies to develop an E. coli strain capable of efficiently assimilating FA. The rTHF cycle was first established by the introduction of M. extorquens ftl and the replacement of native folD gene with the M. extorquens fch and mtd genes, as M. extorquens Fch and Mtd are unifunctional and not allosterically inhibited by 10‐CHO—THF.[ 31 ] Next, the native gcvTHP operon was overexpressed to increase gcv reaction and the native lpd gene encoding lipoamide dehydrogenase, which supply NADH to the gcv complex, was overexpressed to enhance NADH supply. Furthermore, the native serA gene was deleted to ensure L‐serine is only produced from FA and CO2 only. Engineering of the rTHF‐rgcv pathway in the study by Yishai et al. was settled at this stage and the engineered E. coli strain reported in this study synthesized L‐serine from FA and CO2 with high efficiency; up to 90% and 10% of proteinogenic L‐serine and total pyruvate, respectively, were produced from FA and CO2. Further metabolic engineering strategies were employed in the study by Bang and Lee to derive a better FA assimilating E. coli strain. The gcvR gene encoding transcriptional regulator of glycine cleavage complex was deleted and the native gcvTHP operon was overexpressed by replacing the native promoter to a strong trc promoter. Next, the pfl gene encoding Pfl was deleted to prevent degradation of pyruvate to FA and acetyl‐CoA. Finally, the Candida boidinii fdh gene encoding NAD+ utilizing Fdh was introduced to reduce the engineered strain's dependence on glucose. The final engineered E. coli strain synthesized 98% and 15% of proteinogenic L‐serine and total pyruvate, respectively, from FA and CO2, which is better than that reported in the study by Yishai et al.[ 30 ] Due to previous studies on the development of efficient synthetic FA assimilation pathways, FA can be utilized to produce chemicals in E. coli. However, the metabolically engineered strains’ dependencies on other carbon sources (e.g., glucose) for cell growth were still unresolved even at this stage. Thus, ALE and/or rational metabolic engineering were further carried out to develop the formatotrophic E. coli strain capable of growing solely from FA and CO2.
4. Development of a Synthetic Formatotroph Capable of Growing on Formic Acid and CO2
4.1. Development of a Synthetic Formatotroph Using ALE
In the case of formatotrophic E. coli, the FA assimilation pathway synthesizes intracellular metabolites such as nucleotides, cell wall, and lipids from FA, while Fdh regenerates NADH and NADPH using FA to provide cellular energy and reducing power required for FA assimilation and intracellular metabolite synthesis. However, the metabolically engineered E. coli strains equipped with the rTHF‐rgcv pathway and Fdh could not grow using FA and CO2 as sole carbon sources,[ 35 ] indicating that the metabolic system of the engineered E. coli strain needs to be further modified to achieve formatotrophic growth.
Although the overall metabolism of E. coli is well studied, the complexity of the metabolic system makes the identification of engineering targets (i.e., metabolic pathways, enzymes, and regulatory proteins) and selection of optimal methods for engineering those targets in E. coli difficult. Since the ultimate objective of metabolic engineering in this case is constructing a strain capable of growing solely on FA and CO2, actual cultivation of all rationally engineered strains needs to be performed to examine the effectiveness of metabolic engineering. Since this is quite labor intensive, ALE can be an alternative strategy to construct a synthetic formatotroph while avoiding such difficulties (Figure 1).
In a previous study, the Rubisco‐dependent heterotrophic parental E. coli strain was developed by introducing the Synechococcus elongatus phosphoribulokinase, Rhodospirillum rubrum Rubisco, and Pseudomonas sp. 101 Fdh, while deleting the pfkAB and zwf genes encoding phosphofructokinase and 6‐phosphate‐1‐dehydrogenase, respectively.[ 33 ] The parental strain, which was constructed to convert pentose sugar (i.e., xylose) to biomass precursors only through the carboxylation by Rubisco,[ 51 ] was cultured in a xylose‐limited chemostat at a dilution rate of 0.02 h−1 using M9 minimal medium supplemented with excess amount of sodium FA (30 mm) and continuous sparging of CO2‐enriched air (10 vol% of CO2 and 90 vol% of air). Keeping the cells under constant starvation provided a strong selection pressure to the cells and forced them to utilize CO2, while oxidizing FA using Fdh to produce energy source. After 350 days of chemostat culture (xylose concentration reached 0 g L−1 at this point), cells began to exhibit formatotrophic growth and the evolved strain isolated from the culture broth was capable of growing solely on FA and CO2 from an initial OD 600 of 0.01 to an OD 600 of 0.28 in 120 h with a doubling time of 18 ± 4 h (Table 2). To identify the mutations occurred in the genomic DNA of evolved strains, six clones were isolated at different chemostat culture time points and whole genome sequencing was performed. Among the mutation sites identified in the genome, mutations in the prs (encoding ribose‐phosphate diphosphokinase), pgi (encoding glucose 6‐phosphate isomerase), aroH (encoding 2‐dehydro‐3‐deoxyphosphoheptonate aldolase), and eno (encoding enolase) genes were speculated to have potentially contributed to formatotrophic growth by fine‐tuning of the CBB cycle flux.[ 51 , 52 , 53 ] Further studies are needed to validate these assumptions. In addition, the maximum cell density (e.g., OD 600 of 0.28; Table 2) of the evolved E. coli strain was too low for feasible applications in microbial chemical production.
In another study, the rTHF‐rgcv pathway and Pseudomonas sp. 101 Fdh were introduced in a serine‐auxotrophic E. coli strain, which was constructed by deleting the ltaE (encoding L‐threonine aldolase), kbl (encoding 2‐amino‐3‐ketobutyrate CoA ligase), and aceA (encoding isocitrate lyase) genes and replacing the native promoters of serA and glyA genes with stronger promoters in the genome, to achieve formatotrophic growth of E. coli.[ 34 ] As a result, the engineered strain showed formatotrophic growth solely on FA and CO2 from an initial OD 600 of 0.03 to 0.4 in 240 h with a doubling time of 70 h. To further enhance formatotrophic growth, a short‐term ALE was carried out by cultivating the cells in test tubes containing M9 minimal medium supplemented with 30 mm of sodium FA and continuous sparging of CO2‐enriched air (10 vol% CO2 and 90 vol% air). When the cell concentration reached an OD 600 of 0.4, cells were transferred to a fresh culture medium to start a new cultivation (an initial OD 600 of 0.03–0.05). After 13 serial cultivations (≤40 generations), the evolved strain grew up to an OD 600 of 1.0 with a significantly shortened doubling time of 7.7 h (Table 2). In addition, the evolved strain showed enhanced FA to biomass conversion yield of 2.3 ± 0.2 gDCW mol FA−1, while the parental strain showed a yield of 1.5 gDCW mol FA−1. To identify the mutations occurred in the genome of the evolved strain, multiple clones exhibiting enhanced formatotrophic growth were isolated and sequenced. As a result, the 5′ untranslated region of the newly introduced Pseudomonas sp. (strain 101) fdh gene and the promoter region of pntAB gene encoding membrane‐bound transhydrogenase were identified to be mutated in all sequenced colonies. To confirm that the two mutant genes had contributed to the enhanced formatotrophic growth of E. coli, the parental E. coli strain was engineered to have the two mutant genes and its formatotrophic growth was compared with the parental E. coli strain. As a result, the parental E. coli strain harboring the two mutant genes showed growth characteristics (doubling time and maximum OD 600) similar to the evolved strain, demonstrating that the two identified mutant genes had contributed to the enhanced formatotrophic growth of E. coli. Despite the great achievement of developing improved formatotrophic growth through metabolic engineering combined with ALE, the maximum cell density reached (OD 600 of ≈1.0) was still too low for its use in the production of chemicals from FA and CO2.
4.2. Development of a Synthetic Formatotroph Using Rational Metabolic Engineering
Although rational metabolic engineering for the development of formatotrophic E. coli is more difficult compared with evolving the strain through ALE, it provides scientific basis on the key metabolic and regulatory factors required for formatotrophic growth and points direction for future studies on developing highly efficient formatotrophs. In a recent study, a synthetic formatotrophic E. coli strain was developed by rational metabolic engineering (Figure 1). The base strain constructed in a previous study[ 31 ] by deleting the gcvR, pflB, and serA genes, replacing the native promoter of gcvTHP operon with a strong trc promoter, and introducing the rTHF‐rgcv pathway and C. boidinii Fdh (CbFdh)[ 35 ] was used for further rational metabolic engineering as follows. First, the ppsA gene was overexpressed by replacing its native promoter with a strong trc promoter and the ppsR gene encoding PEP synthase regulator was deleted to improve cell growth on pyruvate (synthesized from FA and CO2) by reinforcing gluconeogenesis. Enhanced synthesis of essential metabolites, such as nucleotides and lipids, from pyruvate can be achieved by reinforcing gluconeogenesis. Second, the purT gene encoding phosphoribosylglycinamide formyltransferase1, which synthesizes N2‐formyl‐N1‐(5‐phospho‐β‐D‐ribosyl) glycinamide from N1‐(5‐phospho‐β‐D‐ribosyl) glycinamide and FA, was deleted as the E. coli strain expressing both the purT and M. extorquens ftl genes showed inferior growth compared to those expressing the purT and M. extorquens ftl genes individually.[ 54 ] Third, the Arabidopsis thaliana Fdh mutant (mAtFdh) was introduced to resolve NADPH shortage in the cell by generating NADPH from FA; since the base strain also possesses CbFdh for generating NADH from FA, this additional engineering allows generation of both NADH and NADPH from FA. Direct NADPH generation from FA using mAtFdh can enhance formatotrophic growth as two NADPH molecules are necessary to synthesize one pyruvate molecule from FA and CO2. After employing the above three engineering strategies, the newly developed E. coli strain showed formatotrophic growth solely on FA and CO2 and grew up to an OD 600 of 0.285 in 150 h from an initial OD 600 of 0.051 with a doubling time of 60.4 h.
To further improve the formatotrophic growth of the E. coli strain, the overexpression levels of CbFdh and mAtFdh were optimized by employing lower copy number plasmids (copy number of 1–5) since excessive gene expression can adversely affect cell growth under nutrient‐limited culture condition (i.e., minimal medium containing FA and CO2 only). As a result, the formatotrophic E. coli strain showed improved growth solely on FA and CO2 and grew up to an OD 600 of 0.607 in 200 h from an initial OD 600 of 0.06 with a doubling time of 59.9 h. However, the cells could not grow to a higher density, which was found to be due to cell filamentation negatively affecting cell growth.[ 55 ] Cell filamentation seemed to have occurred due to energy‐deficiency as cells were cultivated under nutrient‐limited culture condition.[ 55 ] Hence, the energy efficiency in the cell was improved by enhancing the expression level of cytochrome bo3 ubiquinol oxidase (Cyo; encoded by the cyoABCD gene) while decreasing the expression level of cytochrome bd‐I ubiquinol oxidase (Cyd; encoded by the cydAB and cydX genes) through lowering of the cultivation temperature to 32 °C. It should be noted that Cyo converts reducing powers to ATP more efficiently than Cyd as the proton translocation values of Cyo and Cyd are 2 and 1, respectively.[ 56 ] Moreover, cultivating E. coli at lower temperatures (28 and 33 °C) were reported to increase the Cyo level and decrease the Cyd level compared with 37 °C.[ 57 ] By culturing cells at 32 °C, the challenge with cell filamentation could be resolved and the engineered E. coli strain grew to an OD 600 of 3.59 in 791.5 h from an initial OD 600 of 0.018 solely on FA and CO2 with a doubling time of 103.6 h. Furthermore, the formatotrophic E. coli strain grew to an OD 600 of 11.1, which is the highest cell density reported to date, in 577 h from an initial OD 600 of 0.91 solely on FA and CO2 with a doubling time of 157.6 h in bioreactor culture (Table 2). The achievement in developing a synthetic formatotroph capable of growing to a relatively high maximum cell density presented a possibility of producing chemicals solely from FA and CO2. However, the lower specific growth rate is a key problem that needs to be solved.
4.3. Strategies to Improve Formatotrophic Growth
In order to realize an economically feasible chemical production from FA and CO2, a platform strain capable of growing at a much higher specific growth rate and to a higher cell density on FA and CO2 is needed. Thus, we suggest several engineering strategies to improve formatotrophic growth of E. coli. First, the gene expression levels of Cyo and Cyd at 37 °C need to be fine‐tuned in the formatotrophic strain to prevent cell filamentation by improving the energy conversion efficiency, while allowing higher growth rate compared with 32 °C. This requires a delicate engineering strategy because simply increasing the expression level of Cyo while decreasing the expression level of Cyd can lead to the formation of inclusion bodies.[ 35 ] Furthermore, the cyd genes cannot be deleted from the genome because it is essential for cell growth.[ 58 ] Such fine‐tuning of the gene expression may be performed employing for example the sRNA gene expression knockdown system,[ 59 , 60 ] which has been demonstrated to be useful for optimizing the expression levels of multiple genes.
Increased uptake and utilization of FA by the cells can also improve formatotrophic growth as the amount of energy and carbons that can be provided from one mol of FA are less than those generated from one mol of other typical carbon sources (e.g., glucose). It should be noted that one mol of FA and one mol of glucose can provide 2.5 and 32 mol of ATP through oxidative phosphorylation, respectively.[ 31 ] In addition, 5.8 mol of FA is needed to synthesize one mol of pyruvate, while only 0.5 mol of glucose is required to synthesize one mol of pyruvate.[ 31 ] These calculations suggest that FA needs to be transferred into the cells at least ten times faster than glucose to supply similar amount of energy and carbons through FA assimilation. The transfer of FA into the cell can be enhanced by the overexpression of genes corresponding to FA channel[ 61 ] and by increasing FA concentration in the culture medium. Since the FA concentration in the medium cannot be increased to higher than ≈3 g L−1 because of its toxicity to the cells,[ 31 ] FA tolerance of the formatotrophic E. coli strain needs to be enhanced by ALE[ 34 ] and/or metabolic engineering.[ 62 ]
5. Opportunities for the Production of Chemicals Using the Synthetic Formatotroph
5.1. Metabolic Engineering Strategies for Chemical Production
As the development of a formatotrophic E. coli strain capable of growing to a relatively high maximum cell density[ 35 ] presented a possibility for producing chemicals solely from FA and CO2, we list several example chemicals, including LA, L‐alanine, L‐serine, and SA, that can be produced from FA and CO2. In addition, the strategies for the metabolic engineering of formatotrophic E. coli strain employing the rTHF‐rgcv pathway to produce these chemicals are suggested (Figure 4 ).
LA is an important chemical used in the food and pharmaceutical industries.[ 63 , 64 ] Moreover, LA can be used as a monomer for the production of bio‐based poly(LA)[ 65 , 66 ] and its copolymers, such as poly(3‐hydroxybutyrate‐co‐LA).[ 67 ] LA can be produced from FA and CO2 using formatotrophic E. coli strain, which produces pyruvate from FA and CO2, as LA can be synthesized from pyruvate through a single step reaction by lactate dehydrogenase (LdhA; Figure 4). In order to efficiently produce LA using the formatotrophic E. coli strain, the ldhA gene needs to be overexpressed and the pta, ack (encoding acetate kinase), and pfl genes, which convert pyruvate into other byproducts,[ 68 ] can be deleted to increase the metabolic flux from FA and CO2 toward LA production. It should be noted that fine‐tuning of the ldhA gene expression is required to determine the optimal metabolic flux balance between intracellular metabolites production for cell growth and LA production from pyruvate as the formatotrophic E. coli strain is designed to utilize pyruvate for the synthesis of essential metabolites, including nucleotides and lipids. In addition, LA needs to be exported out of the cell rapidly to prevent or minimize LA consumption as it is a more favorable carbon source than FA.[ 69 ] This can be achieved by overexpressing the lldP gene encoding the lactate/H+ symporter.[ 70 ]
To evaluate how efficiently FA can be converted to LA, the maximum theoretical yield of LA from FA was calculated (Figure 4) using the iML1515, a genome‐scale metabolic model (GEM) of E. coli.[ 71 ] The rTHF‐rgcv pathway and Fdh reactions were incorporated in the iML1515 model by including three new reactions; i) FA + NAD → CO2 + NADH, ii) FA + NADP → CO2 + NADPH, and iii) glycine + NAD + THF ↔ CO2 + 5,10‐CH2—THF + NADH + NH4. To simulate LA production solely from FA, the reactions which uptake other carbon sources (e.g., glucose) were blocked in the GEM. The FA uptake reaction flux was set to 1 mmol gDCW−1 h−1 and the requirement for non‐growth associated maintenance energy was set to zero. The GEM simulation was carried out by setting of the maximum export metabolic flux of target chemical (LA or L‐alanine or L‐serine or SA in the cytosol is exported to the extracellular space) as an objective function under aerobic condition (no constraint on O2 uptake reaction). The GEM simulations were performed using cobrapy package with Gurobi Optimizer in Python 3.6 environment.[ 72 ] The maximum theoretical yield of LA calculated by flux balance analysis[ 73 ] is 0.11 mol of LA mol of FA−1 (Figure 4). In comparison, the maximum theoretical yield of LA on glucose is 1.75 mol of LA mol of glucose−1, which is equivalent to 0.29 mol of LA mol FA equivalent−1, as the number of carbons in glucose and FA differ by a factor of 6. Thus, the maximum theoretical yield of LA on glucose is 2.64 times higher than that on FA, which is due to the carbon loss during the generation of reducing power. GEM simulation revealed that 66 mol% of FA is consumed to produce reducing power, while 34 mol% of FA is consumed to produce metabolites including the target chemical.
L‐alanine, which is widely used in the food, pharmaceutical, and veterinary industries,[ 74 , 75 ] is another chemical that can be produced from FA and CO2 using a formatotrophic E. coli strain. In addition, L‐alanine is utilized to synthesize various polymers, such as co‐polyamides.[ 76 , 77 ] L‐alanine can be produced from pyruvate through a single step reaction by alanine dehydrogenase (Ald; Figure 4). In order to efficiently produce L‐alanine using the formatotrophic E. coli strain, the pta, ack, ldhA, and pfl genes need to be deleted to increase the metabolic flux toward L‐alanine formation by preventing pyruvate from being converted to various byproducts.[ 78 ] Moreover, the E. coli Ald, which converts pyruvate to L‐alanine by consuming intracellular metabolites such as L‐glutamate or L‐valine,[ 78 ] needs to be replaced with the heterologous Ald (e.g., Geobacillus stearothermophilus Ald), which converts pyruvate to L‐alanine by consuming NADH, to achieve both formatotrophic growth and L‐alanine production.[ 78 ] Furthermore, the dadA gene encoding D‐amino acid dehydrogenase needs to be deleted to prevent L‐alanine consumption as alanine racemase I and II encoded by the alr and dadX genes, respectively, convert L‐alanine to D‐alanine, which is further converted to pyruvate by the D‐amino acid dehydrogenase.[ 79 ] The maximum theoretical yield of L‐alanine on FA by GEM simulation is 0.14 mol of L‐alanine mol of FA−1 (Figure 4).
L‐serine, which is also widely used in the food, cosmetics, and pharmaceutical industries,[ 80 , 81 , 82 ] is another α‐amino acid that can be directly synthesized through the rTHF‐rgcv pathway in the formatotrophic E. coli strain (Figure 4). In order to efficiently produce L‐serine using the formatotrophic E. coli strain, fine‐tuning of the expression level of the sda gene using metabolic engineering strategies, such as sRNA[ 59 ] or CRISPRi,[ 83 ] is necessary since Sda is an important enzyme influencing both formatotrophic growth and L‐serine production. Moreover, minimizing the reverse reaction activity of the bidirectional GlyA, which degrades L‐serine into glycine and 5,10‐CH2—THF (Figure 4), can be beneficial for enhanced L‐serine production. The reverse reaction activity of GlyA can be reduced by enzyme evolution or replacement of native enzyme with a heterologous enzyme possessing higher forward reaction activity and lower reverse reaction activity.[ 84 ] Overexpression of the eamA gene encoding the cysteine/homoserine transporter would be beneficial to reduce L‐serine degradation by facilitating L‐serine export to the culture medium.[ 85 ] The maximum theoretical yield of L‐serine on FA is 0.16 mol of L‐serine mol of FA−1 (Figure 4).
SA is recognized as one of the most useful bio‐based chemicals due to its use as a precursor for numerous industrially valuable chemicals[ 37 , 86 ] and as a monomer for the synthesis of various bio‐based polymers, including polyesters and polyamides (Nylon x,4).[ 87 ] Unlike LA, L‐alanine, and L‐serine, which are directly produced from pyruvate or the rTHF‐rgcv pathway, a series of reactions from pyruvate are required to produce SA in the formatotrophic E. coli strain. In order to efficiently produce SA using the formatotrophic E. coli strain, metabolic engineering of the formatotrophic E. coli strain needs to be performed for aerobic SA production. As the formatotrophic E. coli strain is cultivated under nutrient‐limited culture condition, O2 supply through aeration is essential to produce ATP from reducing powers. Moreover, reducing powers are generated through the oxidative tricarboxylic acid (TCA) cycle, offering advantages in terms of rapid cell growth and high SA productivity. However, SA cannot be produced in the formatotrophic E. coli strain under aerobic condition due to the presence of succinate dehydrogenase (encoded by the sdhAB gene), which converts SA to fumarate. Thus, the sdhAB gene needs to be deleted to enable SA accumulation in the formatotrophic E. coli strain.[ 88 ] In addition, utilization of oxidative TCA cycle together with the glyoxylate shunt pathway can offer higher SA yield as the glyoxylate shunt pathway does not involve oxidative decarboxylation.[ 86 ] Hence, the iclR gene, encoding the transcriptional repressor for the glyoxylate shunt pathway, needs to be deleted to activate this pathway. SA production from FA and CO2 can be further improved by deleting the poxB (encoding pyruvate dehydrogenase), pta, ack, and ldhA genes, which convert pyruvate to other byproducts,[ 88 ] and by increasing the expression level of Fdh, which was demonstrated to increase SA production through enhanced NADH supply.[ 89 , 90 ] The maximum theoretical yield of SA on FA is 0.11 mol of SA mol of FA−1 (Figure 4).
The maximum theoretical yields of bio‐derived chemicals (including the above example chemicals) on FA are lower than those on glucose due to several reasons including the use of FA to generate reducing powers. This lower maximum theoretical yield can be compensated by the lower cost of FA ($200 ton−1) compared with glucose ($300–400 ton−1) and CO2 utilization contributing to “net zero” vision globally set by using FA derived from CO2.[ 23 ] Since fossil resource‐based production of chemicals is expected to be associated with penalty costs, it is increasingly important to reduce CO2 generation and utilize CO2 for chemical production. Thus, in addition to the lignocellulosics‐based biorefineries currently pursued actively, bio‐based chemical production by formatotrophic microorganisms using FA (derived from CO2) and CO2 as sole carbon sources will be of great importance. To make the one‐carbon biorefinery more economically competitive, other systems that allow supply of reducing powers can be integrated; for example, renewable electricity can be supplied to generate NADH/NADPH, while a majority of FA is used to grow cells and produce desired chemicals.
5.2. Development of Fermentation Processes
Besides the development of a formatotrophic E. coli strain to produce chemicals, establishment of an optimal fermentation process is equally important for enhancing formatotrophic growth and production indices (titer, yield, and productivity) of a target chemical. There are a number of factors that need to be optimized, including culture medium, temperature, pH (and pH controlling agent), aeration, and nutrient feeding strategy (including FA supplementation). Among them, let us examine three factors, aeration, pH controlling agents, and FA feeding strategy, as examples of how these factors need to be considered.
Aeration determines the growth of the formatotrophic E. coli strain, as reducing powers are converted to ATP through oxidative phosphorylation.[ 35 ] Thus, increasing aeration can enhance oxidative phosphorylation, resulting in higher cell growth. To increase aeration, the dissolved O2 level in the culture broth, which is measured to control the aeration in a bioreactor by regulating the rotor speed, needs to be set higher than that of a normal E. coli fermentation. Potential cell damage caused by higher shear stress under these conditions needs to be examined as well. Moreover, increasing air flow rate (or use of pure oxygen) and changing the type of impeller[ 91
] or sparger[ 92 ] can be feasible options for enhancing aeration and to achieve higher formatotrophic growth.[ 93 ]
Selection of the best pH controlling agent is another important factor to develop an optimal fermentation process for the formatotrophic E. coli strain as hydroxide is generated from the consumption of FA ions and increases the pH of the fermentation broth. Thus, supplementation of an acid (e.g., HCl) is required to neutralize the pH of fermentation broth. However, the addition of an acid can be detrimental to cell growth due to the accumulation of toxic compounds (e.g., KCl).[ 94 ] Pure FA can be the most feasible option for controlling the pH of the fermentation since no deleterious compounds are generated from FA. Moreover, controlling of pH and replenishing of FA (as a carbon source) in the bioreactor can be carried out simultaneously by selecting FA as a pH controlling agent. Such “dual purpose” strategy of using FA can simplify the entire bioprocess for chemical production using FA and CO2.
Designing an optimal FA feeding strategy is probably the most important for developing an optimal process for the fermentation of a formatotrophic E. coli strain. FA in the culture broth at medium to high concentrations (tens of mm)[ 35 , 37 ] negatively affects formatotrophic growth by reducing ATP production in the cell as FA inhibits cytochrome c oxidase, which is an enzyme associated with the respiratory electron transport.[ 95 ] Moreover, the cytoplasm acidifies due to the diffusion of protonated FA across the cell membrane and reduces the proton motive force.[ 38 , 95 ] Furthermore, FA concentration above ≈3 g L−1 in the culture broth was found to inhibit growth of E. coli (and some other bacteria such as Mannheimia succiniciproducens) in previous studies.[ 35 , 37 ] Thus, a fed‐batch fermentation process equipped with an automated FA feeding controller needs to be well established to maintain the FA concentration and pH in the culture broth within the optimal range. As mentioned earlier, it will be desirable to increase the FA tolerance of the formatotrophic strain through additional metabolic engineering. This will allow higher FA consumption rate and ultimately lead to higher growth rate and product formation rate.
6. Conclusions
As the world is moving toward “net zero” vision, bio‐based production of fuels, chemicals, and materials from renewable resources is becoming increasingly important. Also, the use of one carbon chemicals such as CO2, CO, and CH4 as substrates for chemical production (thus, one‐carbon biorefinery) has recently been attracting attention. In this paper, we reviewed recent advances in the construction of synthetic FA and CO2 assimilation pathways and the development of formatotrophic E. coli strain. After summarizing current achievements, we raised current challenges for establishing one‐carbon biorefinery together with possible solutions. In addition, we analyzed the possibility of producing several chemicals, together with the strategies for metabolic engineering of the formatotrophic E. coli strain to produce these chemicals. Finally, several factors to be considered to optimize fermentation for efficiently producing chemicals from FA and CO2 were discussed.
In addition to developing an efficient formatotrophic platform strain, it is necessary to establish an optimal FA production system (e.g., electrochemical reduction,[ 20 ] photoreduction,[ 96 ] and hydrogenation of CO2 [ 97 ]), which enables economically competitive production of chemicals from FA and CO2 when coupled with the bioprocess (i.e., fermentative production using a metabolically engineered formatotroph). Current technologies already show satisfactory efficiencies in electrochemical reduction of CO2 to FA (Faradaic efficiency above 90%), and thus significantly reducing the production cost of FA from CO2.[ 21 , 23 ] On the other hand, electrochemical reduction of CO2 to two (e.g., ethanol) or three (e.g., propanol) carbon chemicals is inefficient (Faradaic efficiency ≈50%) mainly due to low conversion efficiency and byproduct formation.[ 98 ] Moreover, only a few chemicals can be produced from electrochemical reduction of CO2 using different kinds of electrocatalysts or changing the electrode potentials,[ 99 ] while many different chemicals can be produced from FA by the formatotrophic microorganisms using the metabolic pathways designed and established for the production of those chemicals.[ 100 ] Therefore, the electrochemical reduction of CO2 to FA followed by FA conversion to other chemicals using the formatotrophic microorganisms is much more advantageous. Studies on integrating electrochemical and fermentation systems for diverse applications are being actively pursued[ 101 ] and various configurations of the integrated system have been explored for efficient electricity‐dependent microbial fermentation.[ 102 , 103 ] With such effort, development of optimal electrochemical–biological hybrid systems for the efficient production of chemicals from FA and CO2 is expected in the near future. When these challenges are resolved, it is expected that various chemicals[ 100 ] can be produced from FA and CO2. We hope that this review will provide guidance and considerations for establishing a sustainable and economical one‐carbon biorefinery for the production of chemicals from FA and CO2.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements
J.B. and J.H.A. contributed equally to this work. This work was supported by the C1 Gas Refinery Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF‐2021M3D3A1A0102210031).
Biographies
Junho Bang received his Ph.D. in Chemical and Biomolecular Engineering from Korea Advanced Institute of Science and Technology (KAIST) and currently is a researcher at LG Chem. His research interest focuses on systems metabolic engineering of microorganisms for C1 gas refinery.
Jung Ho Ahn received his Ph.D. in Chemical and Biomolecular Engineering from Korea Advanced Institute of Science and Technology (KAIST) and currently is a researcher at the BioProcess Engineering Research Center. His research interest focuses on systems metabolic engineering of microorganisms for economical production of chemicals and materials.
Sang Yup Lee is a distinguished professor in the Department of Chemical and Biomolecular Engineering, KAIST. He is currently the Dean of KAIST Institutes, Director of BioProcess Engineering Research Center, and Director of Bioinformatics Research Center. His research interests are metabolic engineering, systems biology and biotechnology, industrial biotechnology, synthetic biology, and nanobiotechnology.
Bang J., Ahn J. H., Lee J. A., Hwang C. H., Kim G. B., Lee J., Lee S. Y., Synthetic Formatotrophs for One‐Carbon Biorefinery. Adv. Sci. 2021, 8, 2100199. 10.1002/advs.202100199
References
- 1. Jones S. W., Fast A. G., Carlson E. D., Wiedel C. A., Au J., Antoniewicz M. R., Papoutsakis E. T., Tracy B. P., Nat. Commun. 2016, 7, 12800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Kumar A., Ergas S., Yuan X., Sahu A., Zhang Q., Dewulf J., Malcata F. X., Langenhove H., Trends. Biotechnol. 2010, 28, 371. [DOI] [PubMed] [Google Scholar]
- 3. Irfan M., Bai Y., Zhou L., Kazmi M., Yuan S., Mbadinga S. M., Yang S. Z., Sand W., Gu J. D., Mu B. Z., Bioresour. Technol. 2019, 288, 121401. [DOI] [PubMed] [Google Scholar]
- 4. Thomas D. M., Mechery J., Paulose V., Environ. Sci. Pollut. Res. 2016, 23, 16926. [DOI] [PubMed] [Google Scholar]
- 5. Yuan M., Kummer M. J., Minteer S. D., Chem. ‐ Eur. J. 2019, 25, 14258. [DOI] [PubMed] [Google Scholar]
- 6. Tlili A., Frogneux X., Blondiaux E., Cantat T., Angew. Chem. Int. Ed. 2014, 53, 2543. [DOI] [PubMed] [Google Scholar]
- 7. Peter S. C., ACS Energy Lett. 2018, 3, 1557. [Google Scholar]
- 8. Salehizadeh H., Yan N., Farnood R., Chem. Eng. J. 2020, 390, 124584. [Google Scholar]
- 9. Erb T. J., Zarzycki J., Curr. Opin. Chem. Biol. 2016, 34, 72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Zhu X. G., Long S. P., Ort D. R., Annu. Rev. Plant Biol. 2010, 61, 235. [DOI] [PubMed] [Google Scholar]
- 11. Greene D. N., Whitney S. M., Matsumura I., Biochem. J. 2007, 404, 517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Lin M. T., Occhialini A., Andralojc P. J., Parry M. A. J., Hanson M. R., Nature 2014, 513, 547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Atsumi S., Higashide W., Liao J. C., Nat. Biotechnol. 2009, 27, 1177. [DOI] [PubMed] [Google Scholar]
- 14. Lee S. Y., Kim Y. S., Shin W., Yu J., Lee J., Lee S., Kim Y., Min J., Green Chem. 2020, 22, 6889. [Google Scholar]
- 15. Flamholz A. I., Dugan E., Blikstad C., Gleizer S., Ben‐Nissan R., Amram S., Antonovsky N., Ravishankar S., Noor E., Bar‐Even A., Milo R., Savage D. F., eLife 2020, 9, e59882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Takeuchi M. H., Morisaki K., Toyooka K., Numata K., PLoS One 2016, 11, e0160981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Savir Y., Noor E., Milo R., Tlusty T., Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 3475. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Whitney S. M., Houtz R. L., Alonso H., Plant Physiol. 2011, 155, 27. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Dey S., Todorova T., Fontecave M., Mougel V., Angew. Chem. Int. Ed. 2020, 59, 2. [DOI] [PubMed] [Google Scholar]
- 20. Yang D., Zhu Q., Chen C., Liu H., Liu Z., Zhao Z., Zhang X., Liu S., Han B., Nat. Commun. 2019, 10, 677. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Agarwal A. S., Zhai Y., Hill D., Sridhar N., ChemSusChem 2011, 4, 1301. [DOI] [PubMed] [Google Scholar]
- 22. Boddien A., Gärtner F., Federsel C., Sponholz P., Mellmann D., Jackstell R., Junge H., Beller M., Angew. Chem. Int. Ed. 2011, 50, 6411. [DOI] [PubMed] [Google Scholar]
- 23. Yishai O., Lindner S. N., Cruz J. G., Tenenboim H., Bar‐Even A., Curr. Opin. Chem. Biol. 2016, 35, 1. [DOI] [PubMed] [Google Scholar]
- 24. Joó F., ChemSusChem 2008, 1, 805. [DOI] [PubMed] [Google Scholar]
- 25. Hailu A., Hailu A., Tamijani A. A., Mason S. E., Shaw S. K., Energy Fuels 2020, 34, 3467. [Google Scholar]
- 26. Albo J., Vallejo D., Beobide G., Castillo O., Castaño P., Irabien A., ChemSusChem 2016, 10, 1100. [DOI] [PubMed] [Google Scholar]
- 27. Crowther G. J., Kosály G., Lidstrom M. E., Am. Soc. Microbiol. 2008, 190, 5057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Yishai O., Goldbach L., Tenenboim H., Lindner S. N., Bar‐Even A., ACS Synth. Biol. 2017, 6, 1722. [DOI] [PubMed] [Google Scholar]
- 29. Tashiro Y., Hirano S., Matson M. M., Atsumi S., Kondo A., Metab. Eng. 2018, 47, 211. [DOI] [PubMed] [Google Scholar]
- 30. Yishai O., Bouzon M., Döring V., Bar‐Even A., ACS Synth. Biol 2018, 7, 2023. [DOI] [PubMed] [Google Scholar]
- 31. Bang J., Lee S. Y., Proc. Natl. Acad. Sci. U. S. A. 2018, 115, E9271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Kim S. J., Yoon J., Im D. K., Kim Y. H., Oh M. K., Biotechnol. Biofuels 2019, 12, 207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Gleizer S., Ben. Nissan R., On Y. M. B., Antonovsky N., Noor E., Zohar Y., Jona G., Krieger E., Shamshoum M., Bar‐Even A., Milo R., Cell 2019, 179, 1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Kim S., Lindner S. N., Aslan S., Yishai O., Wenk S., Schann K., Bar‐Even A., Nat. Chem. Biol. 2020, 16, 538. [DOI] [PubMed] [Google Scholar]
- 35. Bang J., Hwang C. H., Ahn J. H., Lee J. A., Lee S. Y., Nat. Microbiol. 2020, 5, 1459. [DOI] [PubMed] [Google Scholar]
- 36. Lee S. Y., Trends Biotechnol. 1996, 14, 98. [DOI] [PubMed] [Google Scholar]
- 37. Ahn J. H., Seo H., Park W., Seok J., Lee J. A., Kim W. J., Kim G. B., Kim K., Lee S. Y., Nat. Commun. 2020, 11, 1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Warnecke T., Gill R. T., Microb. Cell Fact. 2005, 4, 25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Siegel J. B., Smith A. L., Poust S., Wargacki A. J., Bar‐Even A., Louw C., Shen B. W., Eiben C. B., Tran H. M., Noor E., Gallaher J. L., Bale J., Yoshikuni Y., Gelb M. H., Keasling J. D., Stoddard B. L., Lidstrom M. E., Baker D., Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 3704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Lu X., Liu Y., Yang Y., Wang S., Wang Q., Wang X., Yan Z., Cheng J., Liu C., Yang X., Luo H., Yang S., Gou J., Ye L., Lu L., Zhang Z., Guo Y., Nie Y., Lin J., Li S., Tian C., Cai T., Zhuo B., Ma H., Wang W., Ma Y., Liu Y., Li Y., Jiang H., Nat. Commun. 2019, 10, 1378. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Cotton C. A., Claassens N. J., Benito‐Vaquerizo S., Bar‐Even A., Curr. Opin. Biotechnol. 2020, 62, 168. [DOI] [PubMed] [Google Scholar]
- 42. Zelcbuch L., Lindner S. N., Zegman Y., Vainberg Slutskin I., Antonovsky N., Gleizer S., Milo R., Bar‐Even A., Biochemistry 2016, 55, 2423. [DOI] [PubMed] [Google Scholar]
- 43. Richter F., Leaver‐Fay A., Khare S. D., Bjelic S., Baker D., PLoS One 2011, 6, e19230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Eiben C. B., Siegel J. B., Bale J. B., Cooper S., Khatib F., Shen B. W., Stoddard B. L., Popovic Z., Baker D., Nat. Biotechnol. 2012, 30, 190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Leaphart A. B., Spencer H. T., Lovell C. R., Arch. Biochem. Biophys. 2002, 408, 137. [DOI] [PubMed] [Google Scholar]
- 46. Yang K., Feng C., Lip H., Bruce W. R., O'Brien P. J., Chem.‐Biol. Interact. 2011, 191, 315. [DOI] [PubMed] [Google Scholar]
- 47. Yu H., Liao J. C., Nat. Commun. 2018, 9, 3992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48. He H., Höper R., Dodenhöft M., Marlière P., Bar‐Even A., Metab. Eng. 2020, 60, 1. [DOI] [PubMed] [Google Scholar]
- 49. Yurimoto H., Kato N., Sakai Y., Chem. Rec. 2005, 5, 367. [DOI] [PubMed] [Google Scholar]
- 50. Dev I., Harvey R., J. Biol. Chem. 1978, 253, 4245. [PubMed] [Google Scholar]
- 51. Antonovsky N., Gleizer S., Noor E., Zohar Y., Herz E., Barenholz U., Zelcbuch L., Amram S., Wides A., Tepper N., Davidi D., Bar‐On Y., Bareia T., Wernick D. G., Shani I., Malitsky S., Jona G., Bar‐Even A., Milo R., Cell 2016, 166, 115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Herz E., Antonovsky N., Bar‐On Y., Davidi D., Gleizer S., Prywes N., Noda‐Garcia L., Frisch K. L., Zohar Y., Wernick D. G., Savidor A., Barenholz U., Milo R., Nat. Commun. 2017, 8, 1705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Totir M., Echols N., Nanao M., Gee C. L., Moskaleva A., Gradia S., Iavarone A. T., Berger J. M., May A. P., Zubieta C., Alber T., PLoS One 2012, 7, e32498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Aluri S., Rex K., Varshney U., FEMS Microbiol. Lett. 2015, 362, fnv101. [DOI] [PubMed] [Google Scholar]
- 55. Jeong K. J., Lee S. Y., Appl. Environ. Microbiol. 2003, 69, 1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Calhoun M., Oden K., Gennis R. B., De Mattos M., Neijssel O., J. Bacteriol. 1993, 175, 3020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Gadgil M., Kapur V., Hu W., Biotechnol. Prog. 2008, 21, 689. [DOI] [PubMed] [Google Scholar]
- 58. Baba T., Ara T., Hasegawa M., Takai Y., Okumura Y., Baba M., Datsenko K. A., Tomita M., Wanner B. L., Mori H., Mol. Syst. Biol. 2006, 2, 2006.0008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Na D., Yoo S. M., Chung H., Park H., Park J. H., Lee S. Y., Nat. Biotechnol. 2013, 31, 170. [DOI] [PubMed] [Google Scholar]
- 60. Noh M., Yoo S. M., Kim W. J., Lee S. Y., Cell Syst. 2017, 5, 418. [DOI] [PubMed] [Google Scholar]
- 61. Sawers R. G., Biochem. Soc. Trans. 2005, 33, 42. [DOI] [PubMed] [Google Scholar]
- 62. Hasunuma T., Sanda T., Yamada R., Yoshimura K., Ishii J., Kondo A., Microb. Cell Fact. 2011, 10, 2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Abdel‐Rahman M. A., Sonomoto K., J. Biotechnol. 2016, 236, 176. [DOI] [PubMed] [Google Scholar]
- 64. Okano K., Tanaka T., Ogino C., Fukuda H., Kondo A., Appl. Microbiol. Biotechnol. 2010, 85, 413. [DOI] [PubMed] [Google Scholar]
- 65. Choi S. Y., Cho I. J., Lee Y., Park S., Lee S. Y., Methods Enzymol. 2019, 627, 125. [DOI] [PubMed] [Google Scholar]
- 66. Jung Y. K., Kim T. Y., Park S. J., Lee S. Y., Biotechnol. Bioeng. 2010, 105, 161. [DOI] [PubMed] [Google Scholar]
- 67. Jung Y. K., Lee S. Y., J. Biotechnol. 2011, 151, 94. [DOI] [PubMed] [Google Scholar]
- 68. Yang Y., San K., Bennett G. N., Metab. Eng. 1999, 1, 141. [DOI] [PubMed] [Google Scholar]
- 69. Kaksonen A. H., Plumb J. J., Franzmann P. D., Puhakka J. A., FEMS Microbiol. Ecol. 2004, 47, 279. [DOI] [PubMed] [Google Scholar]
- 70. Hirokawa Y., Goto R., Umetani Y., Hanai T., J. Biosci. Bioeng. 2017, 124, 54. [DOI] [PubMed] [Google Scholar]
- 71. Monk J. M., Lloyd C. J., Brunk E., Mih N., Sastry A., King Z., Takeuchi R., Nomura W., Zhang Z., Mori H., Feist A. M., Palsson B. O., Nat. Biotechnol. 2017, 35, 904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Ebrahim A., Lerman J. A., Palsson B. O., Hyduke D. R., BMC Syst. Biol. 2013, 7, 74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Orth J. D., Thiele I., Palsson B. Ø., Nat. Biotechnol. 2010, 28, 245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Hols P., Kleerebezem M., Schanck A. N., Ferain T., Hugenholtz J., Delcour J., Vos W. M., Nat. Biotechnol. 1999, 17, 588. [DOI] [PubMed] [Google Scholar]
- 75. Lee M., Smith G., Eiteman M., Altman E., Appl. Microbiol. Biotechnol. 2004, 65, 56. [DOI] [PubMed] [Google Scholar]
- 76. Mallakpour S., Dinari M., J. Macromol. Sci., Part A 2011, 48, 644. [Google Scholar]
- 77. Gudeangadi P. G., Uchida K., Tateishi A., Terada K., Masunaga H., Tsuchiya K., Miyakawab H., Numata K., Polym. Chem. 2020, 11, 4920. [Google Scholar]
- 78. Zhang X., Jantama K., Moore J. C., Shanmugam K. T., Ingram L. O., Appl. Microbiol. Biotechnol. 2007, 77, 355. [DOI] [PubMed] [Google Scholar]
- 79. Wild J., Obrępalska B., Mol. Gen. Genet. 1982, 186, 405. [DOI] [PubMed] [Google Scholar]
- 80. Brassier A., Valayannopoulos V., Bahi‐Buisson N., Wiame E., Hubert L., Boddaert N., Kaminska A., Habarou F., Desguerre I., Schaftingen E. V., Ottolenghi C., Lonlay P., Eur. J. Paediatr. Neurol. 2016, 20, 53. [DOI] [PubMed] [Google Scholar]
- 81. Nagasawa M., Otsuka T., Togo Y., Yamanaga M., Yoshida J., Uotsu N., Teramoto S., Yasuo S., Furuse M., Amino Acids 2017, 49, 1561. [DOI] [PubMed] [Google Scholar]
- 82. Sim W., Han I., Lee W., Choi Y., Lee K., Kim D. G., Jung S., Oh S., Lee B., Toxicol. In Vitro 2016, 34, 138. [DOI] [PubMed] [Google Scholar]
- 83. Yao L., Cengic I., Anfelt J., Hudson E. P., ACS Synth. Biol. 2016, 5, 207. [DOI] [PubMed] [Google Scholar]
- 84. Waditee‐Sirisattha R., Sittipol D., Tanaka Y., Takabe T., FEMS Microbiol. Lett. 2012, 333, 46. [DOI] [PubMed] [Google Scholar]
- 85. Mundhada H., Schneider K., Christensen H. B., Nielsen A. T., Biotechnol. Bioeng. 2016, 113, 807. [DOI] [PubMed] [Google Scholar]
- 86. Ahn J. H., Jang Y., Lee S. Y., Curr. Opin. Biotechnol. 2016, 42, 54. [DOI] [PubMed] [Google Scholar]
- 87. Lee J. A., Ahn J. H., Kim I., Li S., Lee S. Y., ACS Sustainable Chem. Eng. 2020, 8, 5604. [Google Scholar]
- 88. Lin H., Bennett G. N., San K. Y., Biotechnol. Bioeng. 2005, 90, 775. [DOI] [PubMed] [Google Scholar]
- 89. Jantama K., Haupt M. J., Svoronos S. A., Zhang X., Moore J. C., Shanmugam K. T., Ingram L. O., Biotechnol. Bioeng. 2008, 99, 1140. [DOI] [PubMed] [Google Scholar]
- 90. Ahn J. H., Bang J., Kim W. J., Lee S. Y., Biotechnol. Bioeng. 2017, 114, 2837. [DOI] [PubMed] [Google Scholar]
- 91. Amanullah A., Serrano‐Carreon L., Castro B., Galindo E., Nienow A. W., Biotechnol. Bioeng. 1998, 57, 95. [DOI] [PubMed] [Google Scholar]
- 92. Druzinec D., Salzig D., Kraume M., Czermak P., Chem. Eng. Sci. 2015, 126, 160. [Google Scholar]
- 93. Cutayar J., Poillon D., Biotechnol. Lett. 1989, 11, 155. [Google Scholar]
- 94. Claassens N. J., Cotton C. A. R., Kopljar D., Bar‐Even A., Nat. Catal. 2019, 2, 437. [Google Scholar]
- 95. Nicholls P., Biochem. Biophys. Res. Commun. 1975, 67, 610. [DOI] [PubMed] [Google Scholar]
- 96. Todorova T. K., Huan T. N., Wang X., Agarwala H., Fontecave M., Inorg. Chem. 2019, 58, 6893. [DOI] [PubMed] [Google Scholar]
- 97. Zhang W., Wang S., Zhao Y., Ma X., Fuel Process. Technol. 2018, 178, 98. [Google Scholar]
- 98. Kim D., Kley C. S., Li Y., Yang P., Proc. Natl. Acad. Sci. U. S. A. 2017, 40, 10560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99. Qiao J., Liu Y., Hong F., Zhang J., Chem. Soc. Rev. 2014, 43, 631. [DOI] [PubMed] [Google Scholar]
- 100. Lee S. Y., Kim H. U., Chae T. U., Cho J. S., Kim J. W., Shin J. H., Kim D. I., Kim Y., Jang W. D., Jang Y., Nat. Catal. 2019, 2, 18. [Google Scholar]
- 101. Lovley D. R., Nevin K. P., Curr. Opin. Biotechnol. 2011, 22, 441. [DOI] [PubMed] [Google Scholar]
- 102. Liu C., Colón B. C., Ziesack M., Silver P. A., Nocera D. G., Science 2016, 352, 1210. [DOI] [PubMed] [Google Scholar]
- 103. Li H., Opgenorth P. H., Wernick D. G., Rogers S., Wu T.‐Y., Higashide W., Malati P., Huo Y., Cho K. M., Liao J. C., Science 2012, 335, 1596. [DOI] [PubMed] [Google Scholar]